Redbiotec launches CMV VLP program

Redbiotec has launched the development of several multi-valent virus-like particles (VLPs) against the Cytomegalovirus (CMV).

mlienert2017-09-29T15:19:52+02:00June 8th, 2010|News|

Company

BRISPR®tech
Other Programs

News & Events
- News & Events
- In the Press

Redbiotec AG
Wagistrasse 23
8952 Schlieren
Switzerland
Tel.: +41 44 738 20 00
Fax: +41 44 738 20 01
contact@redbiotec.ch

© Redbiotec AG | 2006 - 2020 | Disclaimer | Contact

X LinkedIn

Page load link

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT

Go to Top